Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists

<b>Background:</b> The P2Y₁₂ receptor antagonist selatogrel is being developed for subcutaneous self-administration with a ready-to-use autoinjector at the onset of acute myocardial infarction (AMI) symptoms. The unique pharmacological profile of selatogrel (fast, potent, and short-acting...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Chih-hsuan Hsin, Jasper Dingemanse, Andrea Henrich, Corine Bernaud, Martine Gehin, Andreas Krause
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2023-09-01
Serie:	Biomolecules
Soggetti:	emergency treatment injections myocardial infarction P2Y<sub>12</sub> receptor antagonists platelet aggregation
Accesso online:	https://www.mdpi.com/2218-273X/13/9/1365
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!